Cargando…

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease

The rapid spread of COVID-19 has caused a worldwide public health crisis. For prompt and effective development of antivirals for SARS-CoV-2, the pathogen of COVID-19, drug repurposing has been broadly conducted by targeting the main protease (M(Pro)), a key enzyme responsible for the replication of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Kai S., Alex Kuo, Syuan-Ting, Blankenship, Lauren R., Geng, Zhi Zachary, Li, Shuhua G., Russell, David H., Yan, Xin, Xu, Shiqing, Liu, Wenshe Ray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023366/ https://www.ncbi.nlm.nih.gov/pubmed/35815070 http://dx.doi.org/10.1016/j.crchbi.2022.100025

Ejemplares similares

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library
por: Li, Shuhua G., et al.
Publicado: (2022)

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
por: Alugubelli, Yugendar R., et al.
Publicado: (2022)

A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals
por: Ma, Yuying, et al.
Publicado: (2022)

Assessment of the Antibacterial Efficacy of Halicin against Pathogenic Bacteria
por: Booq, Rayan Y., et al.
Publicado: (2021)

Synergism between the Synthetic Antibacterial and Antibiofilm Peptide (SAAP)-148 and Halicin
por: van Gent, Miriam E., et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay
por: Cao, Wenyue, et al.
Publicado: (2022)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies
por: Wang, Yang, et al.
Publicado: (2022)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

The Delivery of the Novel Drug ‘Halicin’ Using Electrospun Fibers for the Treatment of Pressure Ulcer against Pathogenic Bacteria
por: Aburayan, Walaa S., et al.
Publicado: (2020)

Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023)

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
por: Jain, Rashi, et al.
Publicado: (2020)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
por: Yamane, Daiki, et al.
Publicado: (2022)

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
por: Lin, Yuxi, et al.
Publicado: (2021)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Bepridil is potent against SARS-CoV-2 In Vitro
por: Vatansever, Erol C., et al.
Publicado: (2020)

Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study
por: Shen, Jian-Xin, et al.
Publicado: (2023)

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
por: Pinzi, Luca, et al.
Publicado: (2021)

Thermodynamic and structural insights into the repurposing of drugs that bind to SARS-CoV-2 main protease
por: Wan, Shunzhou, et al.
Publicado: (2021)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening
por: Sanachai, Kamonpan, et al.
Publicado: (2022)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
por: Ray, Abhik Kumar, et al.
Publicado: (2022)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations
por: Omer, Samia E., et al.
Publicado: (2022)

Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro
por: Kato, Yoji, et al.
Publicado: (2021)

Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
por: Lipiński, Piotr F.J., et al.
Publicado: (2021)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method
por: Sencanski, Milan, et al.
Publicado: (2020)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease
por: Gogoi, Neelutpal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jnmk4pvphqlnbd3emt0i4rr0u